Supe S J, Sasane J B, Gupta M K
Strahlenther Onkol. 1987 May;163(5):309-13.
Paterson's clinical data about the maximum tolerance doses for various volumes of interstitial implants with Ra-226 delivered in seven days was made use of in deriving volume correction factors phi v and phi'v for TDF and CRE concepts respectively for brachytherapy. The derived volume correction factors phi v for TDF and phi'v for CRE differ from the from the one assumed for CRE by Kirk et al. and implied for TDF by Goitein. A normalising volume of 70 cc has been suggested for both CRE and TDF concepts for brachytherapy. A table showing TDFv, the volume corrected TDF, is presented for various volumes and dose rates for continuous irradiation. The use of this table is illustrated with examples.
帕特森关于七天内植入不同体积镭 - 226组织间插植物的最大耐受剂量的临床数据，被用于分别推导近距离治疗中TDF和CRE概念的体积校正因子φv和φ'v。推导得出的TDF的体积校正因子φv和CRE的φ'v与柯克等人假设的CRE的因子以及戈伊滕隐含的TDF的因子不同。对于近距离治疗的CRE和TDF概念，均建议采用70立方厘米的归一化体积。给出了一个表格，显示了连续照射下不同体积和剂量率的TDFv（体积校正后的TDF）。文中通过示例说明了该表格的用法。
